No. As of October 2024, CDC recommends that adults with immunocompromising conditions who received a dose of PPSV23 in the past and were previously recommended to receive a second PPSV23 dose at least 5 years after that initial PPSV23 dose should now complete their pneumococcal immunization schedule with PCV20 or PCV21 at least 5 years after the PPSV23 dose.
Last reviewed:
November 13, 2024
In October 2024, CDC updated its guidance to state that an adult who received PCV13 should receive PCV20 or PCV21at least 1 year later. PPSV23 is no longer recommended as an option following PCV13.
Last reviewed:
November 13, 2024
ACIP and CDC do not recommend revaccination with a second dose of PPSV23 for adults 19 through 49 with asplenia who receive PCV15 (Vaxneuvance, Merck) followed by PPSV23.
If the adult patient with asplenia had received PCV13 (Prevnar 13, Pfizer) followed by PPSV23 (instead of Vaxneuvance), then CDC recommends administration of a dose of PCV20 or PCV21 at least 5 years after the dose of PPSV23.
Last reviewed:
November 13, 2024
Based on changes to the ACIP recommendations made in October 2024, a second dose of PPSV23 is no longer recommended for any adult. Adults age 19 through 49 years with immunocompromising conditions who received a dose of PCV15 followed by a dose of PPSV23 have received a complete pneumococcal vaccine schedule, and no further doses are recommended. If they received PCV13 and PPSV23, instead of PCV15, CDC recommends a dose of PCV20 or PCV21 should be given 5 years after the first dose of PPSV23, if the patient has have one of the following immunocompromising conditions:
- Kidney disease and on maintenance dialysis
- Kidney disease with nephrotic syndrome
- Asplenia or splenic dysfunction
- Congenital or acquired immunodeficiency, including B-(humoral) or T-lymphocyte deficiency; complement deficiencies, particularly C1, C2, C3, and C4 deficiency; and phagocytic disorders (excluding chronic granulomatous disease)
- Treatment with immunosuppressive drugs or radiation therapy (including treatment for Hodgkin disease, leukemias, lymphomas, malignant neoplasm, and solid organ transplant)
- HIV infection
- Sickle cell disease or other hemoglobinopathies
Last reviewed:
November 13, 2024
They need a dose of PCV20 or PCV21, but not another dose of PPSV23. CDC recommends that people age 50 or older who received PCV13 and either one or two doses of PPSV23 before age 65 should receive a dose of PCV20 or PCV21 at least 5 years after the last pneumococcal vaccine dose. If they received PCV15 followed by PPSV23, they are not recommended to receive any additional pneumococcal vaccine doses at this time.
A patient age 50 or older who received one or two doses of PPSV23 earlier in life but has not received any PCV product, or their history of PCV vaccination is only PCV7 or unknown, is recommended to receive a single dose of a currently recommended pneumococcal conjugate vaccine (PCV15, PCV20, or PCV21) at least one year after the last dose of PPSV23.
Last reviewed:
November 13, 2024
No. This patient should receive a dose of PCV15, PCV20, or PCV21 now. As of October 2024, CDC does not recommend revaccination with PPSV23 for any adult who has received a dose of PPSV23.
Last reviewed:
November 13, 2024
